JP Morgan Chase
RAPP

JP Morgan Chase’s Rapport Therapeutics RAPP Stock Holding History

JP Morgan Chase’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$439K Buy
15,846
+717
+5% +$20.2K ﹤0.01% 5107
2025
Q4 		$459K Buy
15,129
+5,145
+52% +$142K ﹤0.01% 5102
2025
Q3 		$297K Sell
9,984
-551
-5% -$9.83K ﹤0.01% 5303
2025
Q2 		$120K Sell
10,535
-19
-0.2% -$202 ﹤0.01% 5519
2025
Q1 		$106K Buy
10,554
+3,384
+47% +$43.9K ﹤0.01% 5539
2024
Q4 		$127K Buy
7,170
+3,137
+78% +$69.5K ﹤0.01% 5657
2024
Q3 		$82.6K Buy
+4,033
New +$86.7K ﹤0.01% 5772

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase's RAPP Position: Q1 2026 in Review

JP Morgan Chase increased its Rapport Therapeutics (RAPP) stake by 4.7% in Q1 2026, buying an estimated $20.2K and bringing the position to 15,846 shares worth $439K. The position accounts for ﹤0.01% of the portfolio, ranked #5107.

JP Morgan Chase first reported a position in RAPP in Q3 2024 and has held it in 7 quarters since. The position peaked at $459K in Q4 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • JP Morgan Chase held 15,846 shares of Rapport Therapeutics worth $439K as of Q1 2026.
  • JP Morgan Chase bought 717 Rapport Therapeutics shares in Q1 2026, an estimated $20.2K.
  • Rapport Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5107 holding.
  • JP Morgan Chase first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • JP Morgan Chase's Rapport Therapeutics position peaked at $459K in Q4 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.